Sapphire North America

Landmark results in Chlamydia trachomatis Vaccine Research! 🌟   Researchers have analyzed the immunogenicity of two novel recombinant vaccines based on the modified vaccinia virus Ankara (MVA). These vaccines express the chimeric proteins spCTH522 or CTH522:B7, which contain antigens from the most common serovars of Chlamydia trachomatis – the leading cause for sexually transmitted diseases (STDs). Antigen Design: CTH522:B7 is membrane-anchored, while spCTH522 integrates the N-terminal sequence of the major outer membrane protein (MOMP). Immunogenicity Analysis: After immunization, the splenocytes were harvested and restimulated with a pool of overlapping peptides spanning the full spCTH522 sequence. This peptide pool, synthesized by peptides&elephants, allowed precise identification of immune responses. 🔬 Key Findings: Immune Responses: Both vaccines elicited CD4+ T cell responses in C57BL/6J and HLA-transgenic mouse models, but only HLA-transgenic mice demonstrated multifunctional CD8+ T cell responses. Epitope Discovery: Two HLA-A*02:01-restricted epitopes were identified:  - The known 9-mer NMFTPYIGV (MOMP282–290), previously recognized in human samples.  - A newly discovered 10-mer ALWECGCATL (MOMP200–209), which adds to the potential arsenal against Chlamydia. This research highlights the critical role of antigen localization and animal model selection in developing effective vaccines. If you're interested in the details, check out the full blog post linked in the comments.  Literature: Giuseppe Andreacchio, Ylenia Longo, Sara Moreno Mascaraque, Kartikan Anandasothy, Sarah Tofan, Esma Özün, Lena Wilschrey, Dr. Johannes Ptok, Dung Huynh, Joen Luirink, Ingo Drexler. “Viral Vector-Based Chlamydia trachomatis Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.” Vaccines vol. 12,8 944. 22 Aug. 2024, doi:10.3390/vaccines12080944 #VaccineResearch #ChlamydiaTrachomatis #Immunology #PeptidePool #TcellResponse

A recent study highlights the potential of the RBD-SpyCatcher-mi3 nanoparticle vaccine for addressing SARS-CoV-2 variants. By presenting the receptor-binding domain (RBD) multivalently on nanoscaffolds, this approach elicited strong immune responses in mice. Key points: ◾ Broad neutralization of SARS-CoV-2 variants. ◾ High immunogenicity compared to monomeric RBD vaccines. ◾ Potential for use in emerging vaccine strategies. This study underscores the need for further clinical evaluation to assess its suitability as a broadly protective vaccine candidate. https://buff.ly/4gb3bPi #VaccineDevelopment #SARSCoV2Variants #LifeSciences

🔬 The Power of the Humoral Immune Response 🧬 B cell activation and antibody production form the foundation of the body’s defense against pathogens. Through T cell-dependent and independent mechanisms, B cells adapt to produce highly specific antibodies. Key highlights: T Cell-Dependent Activation: CD4+ helper T cells aid B cells in isotype switching and affinity maturation. Germinal Centers: Where antibody affinity improves for effective pathogen targeting. T Cell-Independent Responses: A rapid, though less specialized, immune defense. These processes are essential in vaccine design, immunotherapies, and managing autoimmune conditions. https://buff.ly/4fL9UiU

🔬 Cell Activation and Antibody Production in the Humoral Immune Response 🧫 The humoral immune response, driven by B cells and antibodies, is central to protecting us from infections. From T cell-dependent activation to germinal center formation and T cell-independent responses, the pathways are as fascinating as they are essential. Understanding these mechanisms is paving the way for advances in vaccine development, immunotherapy, and autoimmune disease treatments. 🌟 Immunostep is empowering bioscience research with cutting-edge solutions for flow cytometry—helping scientists unravel these complex processes. Explore our offerings for your next discovery! #Immunology #BCells #AntibodyResearch #BioscienceInnovation https://buff.ly/4fL9UiU

Take advantage of our Navinci Year-End Special and receive 20% off Naveni® in situ Proximity Ligation Assays. Naveni® proximity ligation technology empowers researchers to: - Visualize protein interplay & modifications. - Quantify molecular interactions with precision. - Obtain clean, highly resolved fluorescence images ready for analysis. #ProximityLigation #ResearchTools #LifeSciences https://buff.ly/4g9ZWZe

At Biortus, we’re excited to showcase our expertise in MicroED (Micro-crystal Electron Diffraction)—a cutting-edge approach that bridges the strengths of X-ray crystallography and Cryo-EM. 🔍 MicroED enables fast, high-resolution analysis using just a few small crystals. This technique offers significant advantages for studying small-molecule drug candidates and natural products, making it a powerful tool in drug discovery applications. Check out this video to see MicroED in action and discover the key benefits of using Biortus’ MicroED services!

Read about the application of LipidLaunch™ C14-4 T Cell Exploration Kit from Cayman Chemical in, mRNA Delivery to Activated Primary Human T Cells Using C14-4 Lipid Nanoparticles. #lipidresearch #lipidnanoparticles #lifesciences

🔬 The PRAME 425-433 peptide (SLLQHLIGL)  is a potent target in cancer immunotherapy, derived from the Preferentially Expressed Antigen in Melanoma (PRAME). Since Kessler et al. first characterized PRAME 425-433 in 2001, we’ve known that cytotoxic T lymphocytes recognizing this HLA-A*0201–restricted epitope can selectively target and destroy cells from melanoma, renal cell, lung, breast, and cervical carcinomas. While PRAME 425-433 is expressed in many malignancies, its expression in healthy tissue is almost exclusively restricted to the testes. This makes the PRAME 425-433 epitope a promising focus for adoptive T cell therapies. To create highly avid PRAME-specific T cells, researchers have introduced high-affinity T-cell receptors (TCRs) specifically targeting the PRAME 425-433 epitope. These TCR-engineered T cells could recognize and lyse melanoma, acute myeloblastic leukemia, colon, cervical, lung, and breast cancer cells, while showing low reactivity toward mature dendritic and kidney epithelial cells. To enhance safety, the PRAME T-cell receptor was co-expressed with an inducible caspase-9 suicide switch to allow for controlled elimination of the modified T cells. To boost the persistence of these TCR-engineered T cells, Sailer et al. co-expressed the PRAME-specific T-cell receptor with a chimeric PD1-41BB costimulatory receptor. This combination significantly enhanced IFN-γ secretion, improved cytotoxic capacity, and reduced T cell exhaustion during repeated exposure to tumor cells in vitro. It also demonstrated remarkable anti-tumor effects in mice, even against PD-L1-positive tumors with low PRAME expression. Currently, clinical in vivo studies are underway, testing the efficacy and safety of PRAME-specific TCR-engineered T cells in cancer therapy. You will find PRAME 425-433 (SLLQHLIGL) in our peptide shop for just €60.40, ready for immediate shipment: https://lnkd.in/em-UZA3W Kessler, J H et al., 2001. The Journal of experimental medicine vol. 193,1: 73-88. doi:10.1084/jem.193.1.73 Sailer, N et al., 2022. Cancers (Basel) 14(8): 1998. doi: 10.3390/cancers14081998. #CancerResearch #Immunotherapy #TCellTherapy #PRAME #Oncology

TdB Labs TRITC-Dextran was recently implemented in a study. Recent research into GelMA’s role in regenerative medicine focuses on the effects of photocrosslinking-induced oxidative stress. Using dental pulp stem cell-conditioned medium (DPSC-CM) helped reduce stress, improving cell viability and differentiation. #RegenerativeMedicine #BioMedicalResearch https://buff.ly/4fGM88J

We are pleased to announce the expansion of our portfolio of fully automated in situ proximity ligation assay kits on the BOND RX and RXm, in partnership with Leica Biosystems We are introducing two products with new fluorescence readout: NaveniFlex™ BOND RX Atto647N/Red and Naveni® PD1/PD-L1 BOND RX Atto647N/Red. These products expand the capabilities of in situ proximity ligation assays with automated workflows on the BOND RX/RXm Fully Automated Research Stainer by Leica Biosystems, to achieve increased throughput and consistent high-quality results. Stop by Navinci’s booth #834 at Society for Immunotherapy of Cancer (SITC) meeting this week to find out more! Read more here: https://lnkd.in/eGqMaETH         For Research Use Only. Not for use in diagnostic procedures.